Business Description
Agios Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US00847X1046
Share Class Description:
FRA:8AP: Ordinary SharesTotal Employee Number:
540Description
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 3.18 | |||||
Equity-to-Asset | 2.05 | |||||
Debt-to-Equity | 0.02 | |||||
Debt-to-EBITDA | -0.08 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 16.6 | |||||
Beneish M-Score | -0.54 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 53 | |||||
3-Year EBITDA Growth Rate | -5.1 | |||||
3-Year EPS without NRI Growth Rate | -1.8 | |||||
3-Year FCF Growth Rate | -5.2 | |||||
3-Year Book Growth Rate | 0.7 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 21.65 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 95.28 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 83.61 | |||||
9-Day RSI | 81.6 | |||||
14-Day RSI | 77.23 | |||||
3-1 Month Momentum % | 0.78 | |||||
6-1 Month Momentum % | 9.32 | |||||
12-1 Month Momentum % | -9.79 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 14.19 | |||||
Quick Ratio | 13.59 | |||||
Cash Ratio | 1.93 | |||||
Days Inventory | 1780.83 | |||||
Days Sales Outstanding | 44.29 | |||||
Days Payable | 920 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -2 | |||||
Shareholder Yield % | 0.73 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 90.04 | |||||
Operating Margin % | -719.97 | |||||
Net Margin % | -639.84 | |||||
EBITDA Margin % | -712.01 | |||||
FCF Margin % | -597.82 | |||||
OCF Margin % | -576.03 | |||||
ROE % | -27.28 | |||||
ROA % | -30.65 | |||||
ROIC % | -79.35 | |||||
3-Year ROIIC % | 260.31 | |||||
ROC (Joel Greenblatt) % | -242.59 | |||||
ROCE % | -36.27 | |||||
Years of Profitability over Past 10-Year | 2 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 33.6 | |||||
PB Ratio | 0.93 | |||||
Price-to-Tangible-Book | 0.93 | |||||
EV-to-EBIT | -4.55 | |||||
EV-to-Forward-EBIT | -4.89 | |||||
EV-to-EBITDA | -4.61 | |||||
EV-to-Revenue | 32.79 | |||||
EV-to-Forward-Revenue | 20.79 | |||||
EV-to-FCF | -5.49 | |||||
Price-to-GF-Value | 0.46 | |||||
| Price-to-Net-Current-Asset-Value | 2.97 | |||||
| Price-to-Net-Cash | 59.29 | |||||
Earnings Yield (Greenblatt) % | -21.98 | |||||
FCF Yield % | -17.45 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Agios Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 56.769 | ||
| EPS (TTM) (€) | -6.232 | ||
| Beta | -0.0116 | ||
| 3-Year Sharpe Ratio | 0.29 | ||
| 3-Year Sortino Ratio | 0.43 | ||
| Volatility % | 43.23 | ||
| 14-Day RSI | 77.23 | ||
| 14-Day ATR (€) | 0.820278 | ||
| 20-Day SMA (€) | 26.94 | ||
| 12-1 Month Momentum % | -9.79 | ||
| 52-Week Range (€) | 19.7 - 38.8 | ||
| Shares Outstanding (Mil) | 59.47 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Agios Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Agios Pharmaceuticals Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-10-30 08:00 | In 123 days | ||
| Third quarter earnings results for 2026 | 2026-10-30 | In 122 days | ||
| Second quarter earnings conference call for 2026 | 2026-07-30 08:00 | In 31 days | ||
| Second quarter earnings results for 2026 | 2026-07-30 | In 30 days | ||
| General meeting for 2026 | 2026-06-18 09:00 | 27.20 (+0.00%) | ||
| Guidance call for 2026 | 2026-06-13 09:00 | 24.60 (+0.00%) | ||
| Agios Expands into ITP with Global License Agreement for Next-Generation SYK Inhibitor Cevidoplenib | 2026-06-01 08:30 | 25.80 (+0.00%) | ||
| Guidance call for 2026 | 2026-05-19 11:00 | 23.60 (+0.00%) | ||
| Guidance call for 2026 | 2026-05-12 12:20 | 23.40 (+0.00%) | ||
| First quarter earnings conference call for 2026 | 2026-04-29 08:00 | 20.60 (+0.00%) |
Show
Entries
Agios Pharmaceuticals Inc Frequently Asked Questions
What is Agios Pharmaceuticals Inc(FRA:8AP)'s stock price today?
The current price of FRA:8AP is €33.20. The 52 week high of FRA:8AP is €38.80 and 52 week low is €19.70.
When is next earnings date of Agios Pharmaceuticals Inc(FRA:8AP)?
The next earnings date of Agios Pharmaceuticals Inc(FRA:8AP) is 2026-07-30.
Does Agios Pharmaceuticals Inc(FRA:8AP) pay dividends? If so, how much?
Agios Pharmaceuticals Inc(FRA:8AP) does not pay dividend.
Press Release
Articles on Agios Pharmaceuticals Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers